Journal of Korean Neurosurgical Society

  • 제51권4호
  • /
  • Pages.199-202
  • /
  • 2012
  • /
  • 2005-3711(pISSN)
  • /
  • 1598-7876(eISSN)
대한신경외과학회 (The Korean Neurosurgical Society)
권호 표지
DOI QR코드

DOI QR Code

The Role of Chemotherapy in Anaplastic Astrocytoma Patients

  • Kim, Sung-Kwon (Department of Neurosurgery, Seoul National University College of Medicine) ;
  • Kim, Jin-Wook (Department of Neurosurgery, Seoul National University College of Medicine) ;
  • Kim, Yong-Hwy (Department of Neurosurgery, Seoul National University College of Medicine) ;
  • Kim, Tae-Min (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Chul-Kee (Department of Neurosurgery, Seoul National University College of Medicine)
  • 투고 : 2011.09.01
  • 심사 : 2012.04.15
  • 발행 : 2012.04.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA). Methods: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-COOP group), and 25 patients (29.1 %) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group). Results: The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-COOP, and PCV group, respectively and showed significant differences (RT vs. ACNU-COOP; p=0.039, RT vs. PCV; 0.002, ACNU-COOP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-COOP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities. Conclusion: An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.

키워드

과제정보

연구 과제 주관 기관 : Seoul National University

참고문헌

  1. Bleehen NM, Stenning SP : A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64 : 769-774, 1991 https://doi.org/10.1038/bjc.1991.396
  2. Chang SM, Seiferheld W, Curran W, Share R, Atkins J, Choucair A, et al. : Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813) : implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys 59 : 1122-1126, 2004 https://doi.org/10.1016/j.ijrobp.2004.01.002
  3. Desjardins A, Reardon DA, Vredenburgh JJ : Current available therapies and future directions in the treatment of malignant gliomas. Biologics 3 : 15-25, 2009
  4. Eyre HJ, Eltringham JR, Gehan EA, Vogel FS, Al-Sarraf M, Talley RW, et al. : Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery : a Southwest Oncology Group Study. Cancer Treat Rep 70 : 1085-1090, 1986
  5. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, et al. : Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67 : 121-132, 1983
  6. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D : Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44 : 1479-1483, 1994 https://doi.org/10.1212/WNL.44.8.1479
  7. Kim IH, Park CK, Heo DS, Kim CY, Rhee CH, Nam DH, et al. : Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas : a prospective randomized controlled multicenter phase III trial. J Neurooncol 103 : 595-602, 2011 https://doi.org/10.1007/s11060-010-0427-y
  8. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. : Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas : NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18 : 321-324, 1990 https://doi.org/10.1016/0360-3016(90)90096-3
  9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. : The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 : 97-109, 2007 https://doi.org/10.1007/s00401-007-0243-4
  10. Medical Research Council Brain Tumor Working Party : Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma : a Medical Research Council trial. J Clin Oncol 19 : 509-518, 2001 https://doi.org/10.1200/JCO.2001.19.2.509
  11. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S : Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma : a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17 : 3389-3395, 1999 https://doi.org/10.1200/JCO.1999.17.11.3389
  12. Stupp R, Reni M, Gatta G, Mazza E, Vecht C : Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63 : 72-80, 2007 https://doi.org/10.1016/j.critrevonc.2007.03.003
  13. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. : Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 : 333-343, 1978 https://doi.org/10.3171/jns.1978.49.3.0333
  14. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. : Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 : 1323-1329, 1980 https://doi.org/10.1056/NEJM198012043032303
  15. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. : Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 : 2762-2771, 1999 https://doi.org/10.1200/JCO.1999.17.9.2762